secwatch.observer — SEC 8-K summary
======================================

Issuer:     Greenwich LifeSciences, Inc. (GLSI)
CIK:        0001799788
Form:       8-K
Filed at:   2021-11-10T23:59:59+00:00
Accession:  0001493152-21-027743
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Greenwich LifeSciences updates corporate presentation; highlights GP2 Phase IIb data and partnership discussions
--------------------------------------------------------------------------------

- Combined analysis of 5-year Phase IIb data shows no recurrences in HER2/neu 3+ patients receiving 6 primary injections (p=0.0338).
- Company reports interest from large pharma, regional pharma, and biotech investors regarding licensing and collaboration.
- Discussions include possible GP2 licensing, new investment banking partners, Phase III trial collaboration, and European expansion.
- GP2 treatment was well tolerated with no serious adverse events across 138 patients in 4 clinical trials.
- Phase III clinical trial planned with similar treatment regime to Phase IIb.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799788/000149315221027743/0001493152-21-027743-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799788/000149315221027743/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-21-027743

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer